Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Dong-E-E-Jiao Co.,Ltd. (000423.SZ)
CNY50.05
+0.98 (+2.00%)
CN SHZ Healthcare Drug Manufacturers - Specialty & Generic
Address
78 Ejiao Street 252201
Liaocheng, CN
Liaocheng, CN
CEO
Jinni Sun
Website
dongeejiao.com
IPO
1996-07-29
ISIN CNE0000006Y9
Description
Established in 1952 and headquartered in Liaocheng, China, Dong-E-E-Jiao Co.,Ltd. is a prominent manufacturer and distributor of traditional Chinese remedies, biopharmaceuticals, and wellness food products throughout the Chinese market.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY50.05
+0.98 (+2.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
6M
Beta
0.15
Float Shares
425.35M
Free Float %
66.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.31% | +0.62% | -8.78% | -8.06% | +5.75% | +1.85% | -9.21% | +1.26% | +37.11% | +10.48% | +1,013.36% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
50.05
DCF (Unlevered)
182.24
+264.1%
DCF (Levered)
507.01
+913.0%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
90% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | -1 |
| Buy | 6 | -2 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
9.71
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
9 / 10
Strong MOAT
Composite Rating
A
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
4 / 5
High
P/E Score
2 / 5
Medium
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
★ Strong MOAT
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+12.2% ★ Q1'26: +5.6% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+12.0% Q1'26: +7.6% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+33.1% Q1'26: +0.3% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+29.2% ★ Q1'26: +28.5% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+124.2% ★ Q1'26: +98.7% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-0.2% ★ Q1'26: +0.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.02× ★ Q1'26: 0.03× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 8 Rev. Ana. 1 EPS Ana. |
Dec 2027 9 Rev. Ana. 1 EPS Ana. |
Dec 2028 3 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
5.45B
est: 5.08B (+7.3%)
|
6.32B
est: 6.15B (+2.7%)
|
7.37B
est: 7.29B (+1.2%)
|
7.34B
est: 7.52B (-2.5%)
|
2.97B
est: 3.96B (-25.0%)
|
3.41B
est: 3.35B (+1.8%)
|
3.85B
est: 4.70B (-18.1%)
|
4.04B
est: 4.41B (-8.3%)
|
4.72B
est: 4.74B (-0.5%)
|
5.92B
est: 5.72B (+3.5%)
|
6.64B
est: 6.66B (-0.3%)
|
7.51B
7.42B – 7.63B
+12.7% YoY
|
8.39B
8.03B – 8.86B
+11.7% YoY
|
9.30B
9.03B – 9.64B
+10.8% YoY
|
| EBITDA |
1.85B
est: 1.11B (+66.0%)
|
2.14B
est: 1.35B (+59.2%)
|
2.38B
est: 1.59B (+49.2%)
|
2.41B
est: 1.65B (+46.3%)
|
-479.29M
est: 866.00M (-155.3%)
|
203.79M
est: 732.92M (-72.2%)
|
723.79M
est: 1.03B (-29.6%)
|
998.86M
est: 964.36M (+3.6%)
|
1.39B
est: 1.04B (+34.0%)
|
1.80B
est: 1.55B (+16.5%)
|
2.10B
est: 1.80B (+16.8%)
|
2.03B
2.00B – 2.06B
+12.7% YoY
|
2.27B
2.17B – 2.39B
+11.7% YoY
|
2.51B
2.44B – 2.60B
+10.8% YoY
|
| EBIT |
1.75B
est: 942.69M (+85.7%)
|
2.04B
est: 1.14B (+78.6%)
|
2.29B
est: 1.35B (+69.0%)
|
2.30B
est: 1.40B (+64.4%)
|
-608.74M
est: 734.50M (-182.9%)
|
61.80M
est: 621.63M (-90.1%)
|
583.80M
est: 872.39M (-33.1%)
|
852.27M
est: 817.93M (+4.2%)
|
1.25B
est: 879.52M (+42.0%)
|
1.67B
est: 1.38B (+21.5%)
|
1.94B
est: 1.60B (+21.2%)
|
1.81B
1.78B – 1.83B
+12.7% YoY
|
2.02B
1.93B – 2.13B
+11.7% YoY
|
2.24B
2.17B – 2.32B
+10.8% YoY
|
| Net Income |
1.63B
est: 1.64B (-0.8%)
|
1.85B
est: 1.78B (+3.9%)
|
2.04B
est: 2.03B (+0.6%)
|
2.08B
est: 2.05B (+1.6%)
|
-454.83M
est: -372.77M (-22.0%)
|
43.29M
est: 243.01M (-82.2%)
|
440.44M
est: 631.33M (-30.2%)
|
780.00M
est: 796.47M (-2.1%)
|
1.15B
est: 1.11B (+3.3%)
|
1.56B
est: 1.47B (+5.6%)
|
1.74B
est: 1.75B (-0.9%)
|
1.97B
1.90B – 2.07B
+12.5% YoY
|
2.22B
2.13B – 2.32B
+12.3% YoY
|
2.48B
2.38B – 2.59B
+11.7% YoY
|
| SGA |
1.65B
est: 1.94B (-15.1%)
|
2.06B
est: 2.35B (-12.4%)
|
2.11B
est: 2.79B (-24.1%)
|
2.09B
est: 2.88B (-27.2%)
|
1.59B
est: 1.51B (+4.8%)
|
1.18B
est: 1.28B (-7.8%)
|
1.36B
est: 1.80B (-24.6%)
|
1.68B
est: 1.69B (-0.2%)
|
1.85B
est: 1.81B (+1.9%)
|
2.40B
est: 2.23B (+7.7%)
|
2.53B
est: 2.59B (-2.5%)
|
2.92B
2.89B – 2.97B
+12.7% YoY
|
3.27B
3.12B – 3.45B
+11.7% YoY
|
3.62B
3.52B – 3.75B
+10.8% YoY
|
| EPS |
2.48
est: 2.55 (-2.6%)
|
2.83
est: 2.77 (+2.1%)
|
3.13
est: 3.16 (-0.9%)
|
3.19
est: 3.19 (+0.0%)
|
-0.70
est: -0.58 (-20.8%)
|
0.07
est: 0.38 (-82.2%)
|
0.68
est: 0.98 (-30.7%)
|
1.21
est: 1.24 (-2.3%)
|
1.79
est: 1.73 (+3.3%)
|
2.42
est: 2.29 (+5.5%)
|
2.71
est: 2.73 (-0.8%)
|
3.07
2.96 – 3.22
+12.5% YoY
|
3.45
3.32 – 3.61
+12.3% YoY
|
3.85
3.71 – 4.04
+11.7% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-28 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-27 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-26 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-25 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-22 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-21 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-20 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-19 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-18 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-15 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-14 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-13 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-12 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-11 | A | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 2/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 2/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 2/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
1.39B
OE per share TTM
2.17
Owner's Yield
4.31%
Maintenance CapEx ratio
0.20%
Maint CapEx / Avg PPE
45.4%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 53 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | VanEck - China New Economy ETF CNEW.AX | 0.82% | 576.2K | 0.95% |
| 2 | WisdomTree Emerging Markets SmallCap Dividend Fund DGS | 0.35% | 6.26M | 0.58% |
| 3 | Xtrackers Harvest CSI 500 China A-Shares Small Cap ETF ASHS | 0.20% | 73.1K | 0.65% |
| 4 | HSBC MSCI China A UCITS ETF HMCT.L | 0.09% | 124.3K | 0.30% |
| 5 | JPMorgan Diversified Return Emerging Markets Equity ETF JPEM | 0.09% | 337.2K | 0.44% |
| 6 | Xtrackers Harvest CSI A500 UCITS ETF 1D AH50.L | 0.07% | 11.7K | 0.65% |
| 7 | KraneShares ICBCCS S&P China 500 Index UCITS ETF CHIN.L | 0.05% | 37.3K | 0.55% |
| 8 | WisdomTree Emerging Markets High Dividend Fund DEM | 0.04% | 1.68M | 0.63% |
| 9 | iShares Emerging Markets Equity Factor ETF EMGF | 0.04% | 738.8K | 0.26% |
| 10 | State Street SPDR S&P China ETF GXC | 0.02% | 105.9K | 0.59% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
473.9K
Shares Outstanding
643.98M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Guangyuan Liu | Vice president | — | male |
| Guozheng Li | Vice president | — | male |
| Hongyan Ding | Vice President, Chief Financial Officer, Secretary of the Board & Director | — | male |
| Jinni Sun | President & Director | — | female |
| Liang Zheng | Vice president | — | male |
| Longjian Chen | Vice president | — | male |
| Qingchuan Li | Vice president | — | male |
| Xinhua Li | Vice president | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 000423.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
